Cell membrane blebbing, chromatin condensation, genomic DNA fragmentation, and the exposure of particular phagocytosis signaling molecules on the cell surface are just a few of the distinctive morphological and biochemical features of the cell death process known as apoptosis. Apoptosis-initiated cell death is distinct from necrosis-induced cell death. Apoptotic death, in contrast, is silent and orderly. Necrotic cells are typically recognized as a danger signal by the immune system, which causes inflammation.
There are two main methods for inducing apoptotic cell death: The intrinsic pathway, also known as the Bcl-2-regulated or mitochondrial pathway, is strictly regulated by the BCL-2 family of proteins and is activated by a variety of developmental cues or cytotoxic insults, such as viral infection, DNA damage, and growth-factor deprivation.The tumor necrosis factor (TNF) receptor family members, such as Fas or TNF receptor-1 (TNFR1), which contain an intracellular death domain and can recruit and activate caspase-8 through the adaptor protein Fas-associated death domain (FADD; also known as MORT1) at the cell surface, are what initiate the extrinsic or death-receptor pathway. Without the involvement of the BCL-2 family, this recruitment results in the subsequent activation of downstream (effector) caspases like caspase-3, -6, or -7.
Numerous human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome), may be influenced by changes in cell survival, according to studies. Some of these diseases may not progress naturally unless specific therapies that change the apoptotic threshold are used.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V35256 | SSK1 | 2629250-69-5 | SSK1, a senescence-specific killer compound, is a β-galactosidase-targeted precursor that reduces inflammation. |
|
V35254 | STAT3-IN-18 | 2668267-41-0 | STAT3-IN-18 (compound SPP) is a platinum(IV) complex with a pterostilbene-derived axial ligand. |
|
V35253 | STAT3-SH2 domain inhibitor 1 | 2816059-41-1 | STAT3-SH2 domain inhibitor 1 is a potent inhibitor of Src homology 2 (SH2) STAT3 domain (STAT3-SH2 domain) with a Kd of 1.57 μM. |
|
V52672 | Stavudine-d4 (stavudine d4) | 1219803-67-4 | Stavudine-d4 is the deuterated form of Stavudine. |
|
V54929 | Stellasterol | 2465-11-4 | Stellasterol is a naturally occurring compound. |
|
V56392 | Stem bromelain (stem bromelain) | 37189-34-7 | Stem bromelain (EC 3.4.22.32) is a cysteine protease extracted from pineapple (Ananas comosus) stems. |
|
V54064 | Stephanine ((-)-Stephanine; l-Stephanine) | 517-63-5 | Stephanine ((-)-Stephanine) is an isoquinoline aporphine-type alkaloid. |
|
V34689 | Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) | 38937-66-5 | Suberoyl bis-hydroxamic acid (Suberohydroxamic acid; SBHA) is a competitive, cell-permeable (penetrable) inhibitor of HDAC1 and HDAC3 with ID50 values of 0.25 μM and 0.30 μM, respectively. |
|
V52887 | Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) | 128802-78-8 | Suc-Ala-Leu-Pro-Phe-pNA (Suc-ALPF-pNA) is a substrate of FK-506 binding protein (FKBP). |
|
V52785 | Sulfasalazine-d4 (sulfasalazine d4) | 1346606-50-5 | Sulfasalazine-d4 is the deuterated form of Sulfasalazine. |
|
V52671 | Sunitinib-d4 (Sunitinib d4) | 1126721-79-6 | Sunitinib-d4 is the deuterated form of Sunitinib. |
|
V2328 | SW-106065 | 62289-81-0 | SW106065 is an inducer of apoptosis in malignant peripheral nerve sheath tumors (MPNST). |
|
V35238 | SZM-1209 | 2919801-86-6 | SZM-1209 is an orally potent and specific RIPK1 inhibitor (antagonist) with a Kd of 85 nM. |
|
V34669 | T-1101 tosylate (TAI-95 tosylate) | 2250404-95-4 | T-1101 tosylate (also known as TAI95 tosylate) is a potent inhibitor ofHec1/Nek2 (Highly expressed in cancer 1 / NIMA-related kinase 2)with antitumor activity. |
|
V35234 | T025 | 2407433-00-3 | T025 is an orally bioactive Cdc2-like kinase (CLK) inhibitor (antagonist) with Kds of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2 respectively. |
|
V35231 | Tabalumab (LY2127399) | 1143503-67-6 | Tabalumab (LY2127399) is a humanized anti-BAFF (B cell activating factor) monoclonal antibody (mAb) (IgG4 type) with neutralizing activity against membrane-bound and soluble BAFF. |
|
V79854 | TACC3 inhibitor 1 | TACC3 inhibitor 1 is a potent, BBB (blood-brain barrier) permeable (penetrable) TACC3 inhibitor. | |
|
V52465 | Taccalonolide E | 134954-57-7 | Taccalonolide E is a microtubule stabilizer that causes apoptosis in cancer/tumor cells. |
|
V52771 | Tacrolimus-13C,d2 (FK506-13C,d2; Fujimycin-13C,d2; FR900506-13C,d2) | 1356841-89-8 | Tacrolimus-13C,d2 is a 13C and deuterium labelled Tacrolimus. |
|
V52569 | Tamoxifen-d3 (tamoxifen-d3; ICI 47699-d3; (Z)-Tamoxifen-d3; trans-Tamoxifen-d3) | 508201-30-7 | Tamoxifen-d3 is the deuterated form of Tamoxifen. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
